Table 3.
Disorders | Main types | Main metabolic changes | Functional phenotypes |
---|---|---|---|
Tumors | TAMs (M2) (141, 142) | 1) Increased mitochondrial respiration (64); 2) Reduced glycolysis (64) |
1) Combination and secretion of galectin-3 (143) |
2) Activation of ROS (143) | |||
3) Induced HIF-1α (144) | |||
Obesity and Diabetes | (M1) (81, 145) |
1) Reducing lipid transportation (146, 147); 2) Increased glycolysis (66) |
Production of ROS (148) |
Atherosclerosis | M1 (149) | Increased glycolysis (150) | 1) Proinflammatory phenotype (149, 150) |
2)Reduced phagocytic activity (151) | |||
3) Production of foam cells (146, 152) | |||
Injury and Repairation | M1 → M2 (153) | Activation of glycolysis, the TCA cycle, the PPP, FAS and FAO (154) | Transform from proinflammatory to reparative phenotype timely (153, 154) |
Pregnancy- related diseases | a mixed group (155, 156) |
Still being studied | Dynamic changes of phenotypes, M1 → M1/M2 → M2 (137–139, 156) |
TAMs, tumor-associated macrophages; PPP, pentose phosphate pathway; TCA, tricarboxylic acid; FAS, fatty acid synthesis; FAO, fatty acid oxidation.